Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Single-Dose Bioavailability Study of Two Formulations of Ibuprofen and Pseudoephedrine Hydrochloride Tablets

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03429738
Recruitment Status : Completed
First Posted : February 12, 2018
Last Update Posted : February 12, 2018
Sponsor:
Collaborator:
Pharma Medica Research, Inc.
Information provided by (Responsible Party):
Institut für Pharmakologie und Präventive Medizin

Brief Summary:
Evaluation of the comparative bioavailability between two oral formulations containing ibuprofen 200 mg and pseudoephedrine 30 mg after a single dose in healthy subjects under fasting conditions.

Condition or disease Intervention/treatment Phase
Pain, Head Pain, Acute Pain, Back Fever Drug: Ibuprofen/Pseudoephedrine HCl 200/30 mg Film-Coated Tablets Drug: RhinAdvil Rhume 200 mg/30 mg Film-Coated Tablets Phase 1

Detailed Description:
Ibuprofen is one of the most often used non steroidal antiinflammatory drug (NSAR) in the management of mild to moderate pain and inflammation. Combined with the sympathomimetic pseudoephedrine as decongestant it is widely used in colds or fever. The purpose of this phase-I-study was to evaluate the comparative bioavailability between a combination of 200 mg ibuprofen and 30 mg pseudoephedrine film-coated tablets to the reference formulation RhinAdvil Rhume® 200 mg/30 mg (Wyeth Santé Familiale, France).

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 66 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Intervention Model Description: open-label, single-dose, randomized, two-period, two-treatment, twosequence, crossover, comparative bioavailability study.
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Single-Dose, Comparative Bioavailability Study of Two Formulations of Ibuprofen and Pseudoephedrine Hydrochloride 200 mg/30 mg Tablets Under Fasting Conditions
Actual Study Start Date : April 27, 2014
Actual Primary Completion Date : May 5, 2014
Actual Study Completion Date : May 5, 2014


Arm Intervention/treatment
Experimental: Experimental Drug
Drug: Ibuprofen/Pseudoephedrine HCl 200/30 mg Film-Coated Tablets Temmler Werke GmbH/ Part of Aenova Group, Germany, Intervention: one tablet administered after an overnight fast of at least 10 hours
Drug: Ibuprofen/Pseudoephedrine HCl 200/30 mg Film-Coated Tablets
Experimental drug
Other Name: Ibuprofen/Pseudoephedrine/test product

Active Comparator: Active Comparator
Active Comparator: RhinAdvil Rhume 200 mg/30 mg Film-Coated Tablets Wyeth Santé Familiale, France, Intervention: one tablet administered after an overnight fast of at least 10 hours
Drug: RhinAdvil Rhume 200 mg/30 mg Film-Coated Tablets
Active Comparator
Other Name: RhinAdvil




Primary Outcome Measures :
  1. AUC(0-t) (area under the analyte concentration versus time curve) of ibuprofen and pseudoephedrine, respectively [ Time Frame: 7 days (± 3 hours) ]
    The 90% confidence intervals of the relative mean plasma (1S,2S)- pseudoephedrine and (S) ibuprofen AUC should be between 80.00 and 125.00%

  2. maximum serum concentration of ibuprofen and pseudoephedrine, respectively [ Time Frame: 7 days (± 3 hours) ]
    The 90% confidence intervals of the relative mean plasma (1S,2S)- pseudoephedrine and (S) ibuprofen Cmax should be between 80.00 and 125.00%



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Healthy, non-smoking, male and female subjects, 18 years of age or older.
  2. BMI ≥ 18.5 and 30.0 kg/m2
  3. No clinically significant findings in vital signs measurements.
  4. No clinically significant abnormal laboratory values.
  5. No clinically significant findings in a 12-lead electrocardiogram (ECG).
  6. No significant diseases.
  7. Willing to use an acceptable, effective method of contraception.
  8. Be informed of the nature of the study and give written consent prior to any study procedure.
  9. Have no clinically significant findings from a physical examination.

Exclusion Criteria:

  1. Known history or presence of any clinically significant medical condition.
  2. Known or suspected carcinoma.
  3. History or presence of ulcerative colitis, diverticulosis, Crohn's disease, or gastrointestinal ulcer, perforation, or haemorrhage.
  4. Known history or presence of auto-immune disorders, gastrointestinal toxicity, or a risk of gastrointestinal bleeding or gastrointestinal tract irritation.
  5. Known history or presence of cardiovascular disease, heart failure, tachycardia, hypertension, angina pectoris, hyperthyroidism, psychosis, seizures, risk of urinary retention, diabetes, phaeochromocytoma, closed angle glaucoma, chronic rhinitis, or prostatic enlargement.
  6. Known history or presence of angioedema.
  7. Known history or presence of galactose or fructose intolerance, sucraseisomaltase insufficiency, Lapp lactase insufficiency, galactosemia, or glucose-galactose malabsorption syndrome.
  8. Known history of severe skin reactions (e.g. exfoliative dermatitis, SJS, and TEN).
  9. Known history or presence of bronchial asthma or allergic disease resulting in bronchospasm.
  10. Presence of hepatic or renal dysfunction.
  11. Presence of clinically significant gastrointestinal disease or history of malabsorption within the last year.
  12. Presence of a medical condition requiring regular medication (prescription and/or over-the-counter) with systemic absorption.
  13. History of drug or alcohol addiction requiring treatment.
  14. History of gastrointestinal bleeding or perforation when previously taking NSAIDs.
  15. Positive test result for HIV, Hepatitis B surface antigen or Hepatitis C antibody.
  16. Positive test result for urine drugs of abuse (cannabinoids, opiates, amphetamines, cocaine, phencyclidine, tricyclic antidepressants, barbiturates, methadone and benzodiazepines) or urine cotinine.
  17. Difficulty fasting or consuming standard meals.
  18. Does not tolerate venipuncture.
  19. Use of tobacco or nicotine-containing products within 6 months prior to drug administration.
  20. On a special diet within 30 days prior to drug administration (e.g., liquid, protein, raw food diet).
  21. Participated in another clinical trial or received an investigational product within 30 days prior to drug administration.
  22. Donation or loss of whole blood (including clinical trials):

    • 50 mL and ≤ 499 mL within 30 days prior to drug administration
    • 500 mL within 56 days prior to drug administration.
  23. Females who:

    Have discontinued or changed the use of implanted, intrauterine, intravaginal, or injected hormonal contraceptives within 6 months prior to dosing; Have discontinued or changed the use of oral or patch hormonal contraceptives within 1 month prior to drug administration; Are pregnant (serum hCG consistent with pregnancy); or Are lactating.

  24. Have had a tattoo or body piercing within 30 days prior to drug administration.
  25. Known history or presence of hypersensitivity or idiosyncratic reaction to ibuprofen, pseudoephedrine, NSAIDs, or any other drug substances with similar activity or any of the excipients in the drug products
  26. Use of drugs in the phenethylamine and amphetamine chemical classes within 14 days prior to drug administration.
  27. Use of NSAIDs (including cyclo-oxygenase-2 selective inhibitors) aspirin, corticosteroids, anticoagulants, selective serotonin-reuptake inhibitors, antihypertensives, diuretics, cardiac glycosides, lithium, methotrexate, cyclosporin, mifepristone, tacrolimus, zidovudine, linezolid, dopaminergic alkaloids, quinolone antibiotics, terpene derivatives, clobutinol, atropine, local anaesthetics, MAO inhibitors, vasoconstrictors, alpha sympathomimetic drugs, or anti-platelet agents within 30 days prior to drug administration.
  28. Use of any drugs known to induce or inhibit hepatic drug metabolism within 30 days prior to drug administration. (e.g. barbiturates, carbamazepine, phenytoin, glucocorticoids, omeprazole, antidepressants (SSRI), cimetidine, diltiazem, macrolides, imidazoles, neuroleptics, verapamil, fluoroquinolones, antihistamines).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03429738


Locations
Layout table for location information
Canada, Ontario
Pharma Medica Research Inc.
Toronto, Ontario, Canada, MIS 3V6
Sponsors and Collaborators
Institut für Pharmakologie und Präventive Medizin
Pharma Medica Research, Inc.
Investigators
Layout table for investigator information
Study Director: Latifa Yamlahi, MD Pharma Medica Research, Inc.

Layout table for additonal information
Responsible Party: Institut für Pharmakologie und Präventive Medizin
ClinicalTrials.gov Identifier: NCT03429738     History of Changes
Other Study ID Numbers: PMRI study number 2014-3489
First Posted: February 12, 2018    Key Record Dates
Last Update Posted: February 12, 2018
Last Verified: February 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Plan Description: no IPD to be shared

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Institut für Pharmakologie und Präventive Medizin:
Ibuprofen
phase-I-study
pharmacokinetic
combination therapy
bioavailability
bioequivalence
pseudoephedrine hydrochloride
Additional relevant MeSH terms:
Layout table for MeSH terms
Ibuprofen
Acute Pain
Back Pain
Headache
Pain
Neurologic Manifestations
Signs and Symptoms
Pseudoephedrine
Ephedrine
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Inflammatory Agents
Antirheumatic Agents
Cyclooxygenase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Bronchodilator Agents
Autonomic Agents
Anti-Asthmatic Agents
Respiratory System Agents
Nasal Decongestants
Vasoconstrictor Agents
Central Nervous System Stimulants
Sympathomimetics
Adrenergic Agents
Neurotransmitter Agents